XBiotech Announces Data From Its Phase II Portion Of Multicenter TASKIN Clinical Study Meets Pre-Specifed Primary Efficacy Success Criterion Under Simon Two-Stage Design; 61.3% Participants In Vilamakitug Experimental Arm Were Alive, Surpassing Threshold Of 42, More Surviving Patients

XBiotech Inc. (NASDAQ: XBIT) reported positive results from the Phase II portion of its TASKIN clinical trial, demonstrating that 61.3% of participants in the vilamakitug experimental arm were alive at the 12-month mark, exceeding the required threshold of 42. The study, which evaluated the effectiveness of XBiotech's anti-IL-1α monoclonal antibody XB2001 combined with standard chemotherapy for patients with refractory metastatic colorectal cancer, showed that 49 out of 80 evaluable patients in the experimental group survived, compared to 55.7% survival in the control group.